Previous 10 | Next 10 |
2024-02-12 07:18:25 ET More on Pfizer Pfizer Is A Great Investment Over The Next Decade; Buy Pfizer: The 6.3% Yield Is A Appealing Pfizer: Simply Too Cheap To Ignore Moderna RSV vaccine lags rival shots in long-term efficacy: TD Cowen Pfizer, Arvinas'...
2024-02-09 15:35:47 ET More on Metagenomi, Inc. Metagenomi Begins Genetic Treatment IPO Rollout Metagenomi prices initial offering at $15 per share Metagenomi Technologies sets terms for $100M IPO Financial information for Metagenomi, Inc. Read the ...
2024-02-09 14:05:35 ET More on Arbutus Biopharma Arbutus Biopharma reports 2023 cash position of ~$132M as of Dec. 31, 2023 Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbut...
2024-02-09 12:14:22 ET More on Moderna Moderna: Fade 2025 Outlook Moderna's Post-Covid Hangover Might Persist For A Few More Years Moderna, Inc. (MRNA) JPMorgan 42nd Annual Healthcare Conference Transcript Moderna RSV vaccine lags rival shots in long-term eff...
2024-02-08 15:32:06 ET More on GSK, Moderna, etc. Pfizer: The 6.3% Yield Is A Appealing Pfizer: Simply Too Cheap To Ignore Pfizer Is Down 54% From Highs, Now Yields 6.1% GSK stock traded in green for seventh straight session GSK RSV vaccine under FDA ...
2024-02-08 06:05:00 ET Moderna (NASDAQ: MRNA) shares skyrocketed in the early stages of the pandemic as the biotech company became one of the first to bring a vaccine to market. That vaccine went on to generate billions of dollars in earnings for Moderna, allowing the company to inv...
2024-02-07 15:05:33 ET Summary Vanza CF triplet achieved non-inferiority compared to TRIKAFTA in lung function measure and achieved statistically significant improvement in sweat chloride levels compared to it. Regulatory applications of Vanza triplet to the FDA and EMA to treat C...
2024-02-07 13:43:49 ET More on S&P 500 Index: A Technical View Of Potential Downside For The Market Sterling Moves Back Into Previous Trading Range, But Will It Hold? The Warning Signs In The Stock Market Are Clear And Present (Technical Analysis) Stocks ...
CAMBRIDGE, MA / ACCESSWIRE / February 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering (NAE), broadly known as one of the highest acknowledgments of achievement in the field, in rec...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...